Linked Life Data

19210138

Source:http://linkedlifedata.com/resource/pubmed/id/19210138

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-2-12
pubmed:abstractText
Several randomized controlled trials indicate that a low density lipoprotein cholesterol (LDL-C) target <2.0 mmol/L is appropriate for individuals at high risk of coronary artery disease (CAD). Recently released Canadian lipid management guidelines (2006) have incorporated this evidence into their recommendations. A cross-sectional study of patients treated with statins for at least 8 weeks (CALIPSO) was used as a basis to project the ability of statin monotherapy in getting high CAD-risk patients to an LDL-C level <2.0 mmol/L.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-55
pubmed:dateRevised
2009-5-19
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study--observational.
pubmed:affiliation
Health economics and outcomes research, Merck Frosst Canada Ltd., Montreal, Canada. martin_senecal@merck.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't